Related by context. All words. (Click for frequent words.) 72 leukemia ALL 69 pediatric acute lymphoblastic 66 Leukemias 66 Chronic lymphocytic leukemia 66 allogeneic HSCT 65 metastatic renal cell 65 AML acute myeloid 65 acute lymphoblastic 65 leukaemias 64 refractory Hodgkin 64 euthymic patients 64 Ph + acute lymphoblastic 64 testicular germ cell 63 metastatic gastric 63 Chronic myeloid leukemia 63 TNF blocker therapy 63 affective psychosis 63 Hodgkin lymphoma HL 63 Chronic lymphocytic leukemia CLL 62 Acute myelogenous leukemia 62 BMPR2 62 SSc 62 clinicopathological 62 haematologic 62 recurrent glioblastoma multiforme 62 diabetes mellitus DM 62 HIV HCV coinfected 62 Renal Cell Carcinoma RCC 62 relapsed ALL 62 malignant neoplasm 62 TTR amyloidosis 62 de novo AML 62 acute myeloid 62 smoldering myeloma 62 nonalcoholic steatohepatitis NASH 62 Brain metastases 62 nonhereditary 62 Waldenstrom macroglobulinemia 62 tumor histology 61 progressive neurodegenerative disorder 61 carcinoid 61 baseline LDH 61 progressive neurodegenerative 61 MYCN amplification 61 Alzheimer Disease AD 61 K ras mutations 61 lymphoproliferative disorders 61 JAK2 V#F 61 chronic myeloid 61 bladder carcinoma 61 Epstein Barr Virus EBV 61 Hepatocellular Carcinoma HCC 61 bronchopulmonary dysplasia BPD 61 acute leukemias 61 metastatic lung cancer 61 etiologic 61 chronic obstructive airway 61 Parkinson Disease PD 61 IPAH 61 psoriatic arthritis PsA 61 nasopharyngeal carcinoma 61 squamous cell lung cancer 61 Genetic susceptibility 61 nonmetastatic 61 MGUS 61 cell acute lymphoblastic 61 refractory metastatic 61 leukemia AML 61 Colon polyps 61 hepatorenal syndrome 61 PCNSL 61 NMIBC 61 chronic HBV 61 mGluR2 NAM 61 prostate cancer CaP 61 T1DM 61 Lung transplantation 61 chronic granulomatous disease 61 taxane refractory 61 HeFH 61 sJIA 61 Gleevec resistant 61 Idiopathic pulmonary fibrosis 61 muscular dystrophy cystic fibrosis 60 autologous transplants 60 metastatic bladder 60 KRAS oncogene 60 biliary tract cancer 60 thetreatment 60 pancreatic adenocarcinoma 60 pretransplant 60 adjuvant tamoxifen 60 complete cytogenetic response 60 oligodendrogliomas 60 acute leukemia AML 60 EGFR mutation status 60 refractory acute myeloid 60 breast cancer subtypes 60 systemic ALCL 60 #q# deletion syndrome 60 allogeneic bone marrow 60 relapsing remitting MS RRMS 60 metastatic kidney 60 malignant lymphoma 60 post transplant lymphoproliferative 60 CP CPPS 60 complement inhibitor eculizumab 60 relapsed MM 60 Glioblastoma Multiforme GBM 60 MCyR 60 comorbid depression 60 cardiac dysfunction 60 Chronic Myeloid Leukemia 60 gastric carcinoma 60 Ivanhoe Newswire Patients 60 cytomegalovirus infection 60 Cholangiocarcinoma 60 aromatase inhibitors AIs 60 gefitinib Iressa 60 malignant lymphomas 60 myeloproliferative neoplasms MPNs 60 follicular lymphoma FL 60 BCIRG 60 carcinoid tumors 60 Genetic variants 60 mutated KRAS 60 Ischemic 60 Myelodysplastic Syndrome 59 HER2 expression 59 ovarian endometrial 59 comorbid disorders 59 Adjuvant chemotherapy 59 TACI Ig 59 prognostic markers 59 Avastin adjuvant 59 kidney allograft 59 chronic rheumatic 59 advanced adenoma 59 Hydroxyurea 59 lung metastasis 59 Mitochondrial dysfunction 59 differentiated thyroid 59 renal cell carcinomas 59 histological subtype 59 vaso occlusive crisis 59 Subtypes 59 KRAS status 59 HER2 overexpression 59 monoclonal gammopathy 59 haematopoietic 59 coinfected patients 59 Virulizin ® 59 SJIA 59 refractory indolent non 59 hereditary predisposition 59 Multicenter AIDS 59 metastatic malignant 59 primary hyperparathyroidism 59 deletion 5q 59 APOE genotype 59 kidney urologic 59 androgen suppression 59 liver transplant recipients 59 VKORC1 59 Iron Overload 59 Lymphocytic 59 alpha1 antitrypsin deficiency 59 Medullary thyroid cancer 59 chronic thromboembolic pulmonary 59 idiopathic pulmonary arterial hypertension 59 leukemia lymphomas 59 susceptibility locus 59 atherothrombotic disease 59 posttransplant 59 IKZF1 59 GBA mutations 59 cirrhosis liver failure 59 prostate carcinoma 59 haematological cancers 59 CR nPR 59 Philadelphia Chromosome Positive 59 imatinib resistance 59 liver transplantations 59 facioscapulohumeral muscular dystrophy 59 thrombocytopenic 59 underwent resection 59 myelogenous leukemia 59 Graft Versus Host 59 Bronchiectasis 59 ATTR CM 59 Adjuvant therapy 59 histologic subtype 59 thromboembolic disease 59 hyperacute 59 visceral metastases 59 familial aggregation 59 endophenotypes 59 Gastrointestinal Stromal Tumors 59 FGFR2 gene 59 recurrent venous thromboembolism 59 Acute myeloid leukemia 59 essential thrombocythemia 59 chorioamnionitis 59 castrate resistant 59 antiphospholipid syndrome 59 GISTs 59 hormone receptor status 59 ependymoma 59 thyrotropin levels 59 ductal adenocarcinoma 59 Glioma 59 LHON 59 nonsmall cell lung cancer 58 pulmonary metastases 58 PNH patients 58 HBeAg negative 58 achieved CCyR 58 hepatic encephalopathy HE 58 amisulpride 58 Myelodysplasia 58 MELAS 58 p# biomarker 58 BEXXAR Therapeutic Regimen 58 neuroendocrine cancers 58 LV dysfunction 58 thyroid carcinoma 58 GSTP1 58 myeloproliferative 58 progressive neurologic 58 CYT# potent vascular disrupting 58 cancer mCRC 58 Gleevac 58 carotid atherosclerosis 58 tumor subtype 58 epithelial tumors 58 endocrine therapies 58 liver histology 58 LHRH receptor positive 58 NR#A# 58 Acute Renal Failure 58 systolic hypertension 58 extramedullary 58 ADPKD 58 metastatic uveal melanoma 58 myeloproliferative neoplasms 58 diabetic kidney 58 familial clustering 58 Myelodysplastic Syndrome MDS 58 cytoreduction 58 nonalcoholic steatohepatitis 58 pulmonary metastasis 58 operable breast cancer 58 pancreatic carcinoma 58 univariate analyzes 58 Evoltra ® 58 gastric carcinogenesis 58 bronchogenic carcinoma 58 clinicopathologic 58 AML MDS 58 Juvenile Idiopathic Arthritis 58 autologous transplantation 58 susceptibility loci 58 Chronic pancreatitis 58 Velcade bortezomib 58 brain metastases originating 58 pharmacologic intervention 58 HYVET 58 aetiology 58 macroglobulinemia 58 COX2 58 Gynecologic Oncology Group 58 gonococcal 58 Intravenous CP 58 Chronic Myelogenous Leukemia CML 58 rituximab Rituxan 58 schizophrenia CIAS 58 Pemphigus 58 MYH9 gene 58 monozygotic twin 58 acute myelogenous leukemia AML 58 lamivudine resistant 58 undergoing radical prostatectomy 58 elacytarabine 58 multiple myeloma MM 58 malignant brain 58 Relapsing remitting MS 58 Glioblastoma multiforme GBM 58 Lipodystrophy 58 Severe Sepsis 58 renal carcinoma 58 MLH1 58 monogenic 58 5q deletion 58 CYP#D# genotype 58 ABCB1 58 Hematologic 58 shorter telomere length 58 multivariate analyzes 58 ANCA associated 58 CIMZIA TM certolizumab pegol 58 EGFR mutation positive 58 autonomic dysfunction 58 HER2 positive cancers 58 Prognostic factors 58 EGFR inhibitors 58 ALI ARDS 58 nonhuman primate model 58 Fabry Disease 58 lymphocytic leukemia 58 circadian genes 58 dyskeratosis congenita 58 HBeAg 58 Safinamide 58 bicuspid aortic valves 58 PTPN# 58 chromosome #p# [002] 58 inherited mutations 58 membranous nephritis 58 proliferative retinopathy 58 Wilms Tumor 58 oncogenesis 58 pathogenic mechanisms 58 statistically significant predictor 58 predisposing factor 58 liver metastasis 58 neuro degenerative disorder 58 multi infarct dementia 57 Digital Mammographic Imaging 57 HbF 57 pCR 57 ErbB2 positive 57 pathological hallmark 57 familial ALS 57 NOD mouse 57 neurocognitive impairment 57 BCR ABL inhibitor 57 Phase #/#a trial 57 psoriasis Crohn disease 57 Preclinical Models 57 acute mania 57 psychosocial functioning 57 HIV seropositive 57 pathophysiological mechanisms 57 chemoresistance 57 skeletal metastases 57 Lafora disease 57 Motesanib 57 Myocardial infarction 57 AA Amyloidosis 57 MabThera Rituxan 57 esophageal squamous cell carcinoma 57 LymphoStat B belimumab 57 adenomatous 57 hormonally sensitive 57 progressive retinal degenerative 57 Decitabine 57 cisplatin resistant 57 rheumatologic 57 refractory colorectal cancer 57 CDH1 57 refractory AML 57 hepatocellular cancer 57 Circulating tumor cells 57 neoadjuvant radiation 57 etiologic factors 57 gastric cardia 57 canakinumab 57 genomic rearrangement 57 Acute lymphoblastic leukemia 57 karyotypes 57 alveolar rhabdomyosarcoma 57 Celsentri Selzentry 57 International Prognostic Scoring 57 TNM staging 57 INCB# [001] 57 relapsed AML 57 TroVax ® 57 DNA methylation patterns 57 thymoma 57 multifactorial disease 57 APOE e4 57 HSCT 57 Thromboembolic 57 Angiotensin converting enzyme 57 Dysregulation 57 nonmelanoma 57 basal cell nevus syndrome 57 hypovitaminosis D 57 metachronous 57 colorectal adenoma 57 lung fibrosis 57 Acute Myelogenous Leukemia 57 ABL1 57 FOLFIRINOX 57 dominantly inherited 57 seropositivity 57 antibody MAb 57 nondiabetic patients 57 allogeneic transplantation 57 MLL2 57 autosomal dominant polycystic kidney 57 Genetic predisposition 57 Lou Gerhig disease 57 non mutated KRAS 57 JMML 57 retrospective cohort 57 comorbid anxiety 57 systemic amyloidosis 57 neuropsychiatric diseases 57 TTF Therapy 57 elevated triglyceride levels 57 Acute Myeloid Leukaemia AML 57 malignant pancreatic 57 HER2 positive metastatic breast 57 pancreatic islet cell 57 torsade de pointes 57 choroidal vasculopathy 57 cMET 57 pathophysiological processes 57 aMCI precursor 57 H. pylori infections 57 Deforolimus 57 Follicular Lymphoma 57 colorectal carcinoma 57 localized prostate 57 Acute myeloid leukemia AML 57 de ath 57 polyp recurrence 57 GRN# 57 coinfection 57 papillary renal cell carcinoma 57 non hodgkin lymphoma 57 #q#.# [001] 57 narcolepsy cataplexy 57 KRAS mutations occur 57 KRAS variant 57 neuropsychological impairments 57 Clusterin 57 socioeconomic gradient 57 underlying pathophysiology 57 mutated K ras 57 poststroke depression 57 RRM1 57 intra abdominal abscess 57 LUX Lung 57 completely resected 57 Doxil ® 57 atypical Hemolytic Uremic Syndrome 57 recurrent glioblastoma 57 Leber congenital amaurosis LCA 57 myeloid leukemia 57 motor neuron degeneration 57 atherothrombotic 57 locoregional recurrence 57 IL#B 57 metastatic neuroendocrine tumors 57 recurrent metastatic 57 Wilms tumors 57 mTOR inhibition 57 Pleural mesothelioma 57 dietary acrylamide 57 Squamous 57 mitochondrial disorders 57 prostate adenocarcinoma 57 inflammatory demyelinating 57 previously untreated follicular 57 preterm newborns 57 Hormone Refractory Prostate Cancer 57 liver scarring 57 sarcomatoid 57 PROSTVAC VF 57 hypereosinophilic syndrome 57 5 HTTLPR 57 bacteraemia 57 phosphorylated tau 57 stratifying patients 57 Parkinson disease multiple sclerosis 57 Malignant Melanoma 57 clinically heterogeneous 57 Ribavirin causes 57 clinically localized prostate 57 ACZ# 57 Leydig cell 57 Brodmann Area 57 agomelatine 57 resected pancreatic cancer 57 CombAT 57 multivariable analysis 57 genetic determinants 57 cytogenetic responses 57 glycated hemoglobin levels 56 effector function 56 Myelodysplastic syndromes MDS 56 Natalizumab 56 ELACYT 56 Anthracycline 56 tumor necrosis 56 functional polymorphism 56 Hutchinson Gilford progeria 56 interferon ribavirin 56 Hepatocellular Carcinoma 56 Epratuzumab 56 postoperative AF 56 neurocognitive function 56 comorbid psychiatric 56 hepatocellular carcinomas 56 seropositive patients 56 Comorbid 56 DQB1 * 56 stage IIIb IV 56 STRIDE PD 56 suboptimal adherence 56 mycosis fungoides 56 Diabetic nephropathy 56 IDH mutations 56 cediranib 56 cardiac repolarization 56 cystic fibrosis chronic pancreatitis 56 BARACLUDE ® 56 thyrotropin 56 presymptomatic 56 cardio renal 56 nonbacterial prostatitis 56 lupus anticoagulant 56 Aortic stenosis 56 leukemia aplastic anemia 56 RRMS patients 56 galiximab 56 hippocampal atrophy 56 imatinib therapy 56 lupus scleroderma 56 TP# mutations 56 postoperative pulmonary 56 genetic variants associated 56 IL 7R 56 molecular mechanisms underlying 56 advanced metastatic prostate 56 clinicopathological features 56 clinically detectable 56 genetic loci 56 BRAF V#E 56 serum parathyroid hormone 56 proband 56 Nicotine dependence 56 HBeAg negative patients 56 NKX2 56 Hp2 2 56 HNSCC 56 leukemia myeloma 56 erlotinib Tarceva 56 acute lymphoid leukemia 56 beta1 integrin 56 susceptibility gene 56 p# activation 56 riociguat 56 neuronal dysfunction 56 cytogenetic abnormalities 56 Glioblastoma multiforme 56 Nonalcoholic Fatty Liver Disease 56 colorectal cancer CRC 56 chlamydial infection 56 HORIZONS AMI trial 56 Leukemia lymphoma 56 cranial radiation 56 CVD mortality 56 familial adenomatous polyposis 56 antiangiogenic therapy 56 LRRK2 mutation 56 molecular abnormalities 56 malignant pleural mesothelioma 56 paricalcitol 56 nonmalignant 56 Non Alcoholic Steatohepatitis 56 stage IIIB IV 56 Entamoeba histolytica 56 metastatic renal 56 relapsed leukemia 56 SPRYCEL ® 56 oblimersen 56 Cell Non Hodgkin 56 Glioblastoma 56 testicular tumors 56 vidofludimus 56 FLT3 56 Genetic variation 56 IL 1ß 56 Sezary syndrome 56 lupus multiple sclerosis 56 Gliomas 56 pulmonary hypertension PH 56 small lymphocytic lymphoma 56 Malignant Glioma 56 biologic pathways 56 juvenile myelomonocytic leukemia 56 Thalomid ® 56 untreated chronic lymphocytic 56 alcoholic hepatitis 56 neurodevelopmental impairment 56 KRAS mutations 56 Gastric Cancer 56 cryptogenic 56 precursor lesions 56 Cognitive dysfunction 56 BR.# study 56 lumiliximab 56 syngeneic 56 CTEPH 56 neuropathologic 56 panobinostat 56 comorbid illnesses 56 allogeneic transplant 56 dyslipidaemia 56 genetic polymorphisms 56 nucleotide analog 56 gastric adenocarcinoma 56 polycystic kidneys 56 vWD 56 Val HeFT 56 genotype phenotype 56 locoregional 56 B streptococcal 56 germline mutations 56 androgen ablation 56 thiopurine 56 clonogenic 56 Nonalcoholic fatty liver 56 autosomal recessive 56 perinatal morbidity 56 immunodeficiency disorders 56 neoplastic 56 Uncontrolled hypertension 56 heavily pretreated 56 transplantation HCT 56 Glioblastoma Multiforme 56 Kaplan Meier analysis 56 VADT 56 diseases fat malabsorption 56 GH deficiency 56 ptau 56 biochemical recurrence 56 sargramostim 56 CIMZIA ™ 56 preserved ejection fraction 56 MGd 56 virological response 56 K ras mutation 56 Subgroup analysis 56 histologies 56 LRP5 56 de novo mutations 56 Enzastaurin 56 preoperative chemotherapy 56 pancreatic endocrine 56 idiopathic thrombocytopenic purpura 56 atheromatous 56 Attention-Deficit/Hyperactivity Disorder ADHD 56 MDS AML 56 BRCA deficient 56 relapsed GBM 56 macroalbuminuria 56 neuro psychiatric disorders 56 chronic periodontitis 56 mesotheliomas 56 perioperatively 56 Acute Decompensated Heart Failure 56 autologous SCT 56 transthyretin amyloidosis 56 relapsed acute myelogenous 56 CARDIA study 56 myopathies 56 prognostic indicators 56 chronic myeloid leukemia CML 56 mediated inhibition 56 antioxidant supplementation 56 multivessel coronary artery 56 pheochromocytoma 56 neuro developmental disorders 56 adjuvant systemic 56 susceptibility genes 56 PhG alpha 1 56 Chronic myeloid leukemia CML 56 renovascular hypertension 56 grade cervical intraepithelial 56 Tesmilifene 56 cranial irradiation 56 neuro endocrine 56 hepatocellular carcinoma HCC 56 underwent surgical resection 56 PRESEPT study 56 SNP rs# [002] 56 TRAIL induced apoptosis 56 hyperparathyroidism 56 mRCC 56 Sprycel dasatinib 56 hematological malignancy 56 Flu Cy 56 indolent lymphoma 56 CALGB 56 resistant hormone refractory 56 causative mutations 56 Arch Intern Med 55 CIMZIA TM 55 non metastatic osteosarcoma 55 afatinib 55 Hepatotoxicity 55 deCODE BreastCancer 55 thalidomide Thalomid 55 hematological diseases 55 recurrent malignant glioma 55 Univariate analysis 55 MTHFD1L gene 55 neurocognitive deficits 55 overt nephropathy 55 comorbid psychiatric disorders 55 nutlin 3a 55 psychiatric comorbidity 55 rheumatic disorders 55 ERalpha 55 antiretroviral naïve 55 Subgroup analyzes 55 atypical hyperplasia 55 advanced neoplasia 55 System IPSS 55 Pseudomonas aeruginosa infections 55 sirtuin activators 55 microdeletion 55 Valvular heart 55 G6PD deficiency 55 catechol O methyltransferase 55 pathogenetic 55 androgen depletion therapy 55 Sipuleucel T 55 squamous histology 55 postoperative radiotherapy 55 osteosarcomas 55 graft dysfunction 55 Opportunistic infections 55 HER2 positivity 55 % CI #.#-#.# [003] 55 Radical prostatectomy 55 neuropathological 55 subclinical atherosclerosis 55 GIST tumors 55 myelofibrosis polycythemia vera 55 CMV infection 55 HNPCC 55 anti angiogenic agents 55 hematopoietic cell 55 antibody mediated 55 Cimzia TM 55 Cytomegalovirus CMV 55 hematopoietic cancers 55 EUROCARE 55 OnDose TM 55 gene rearrangements 55 nonmelanoma skin cancers 55 urological cancers 55 Cloretazine 55 Folfox 55 Neurofibromatosis type 55 grade gliomas 55 microsatellite instability 55 PHPT 55 minimally symptomatic 55 prostate carcinogenesis 55 symptomatic VTE 55 lenalidomide dexamethasone 55 inoperable pancreatic cancer 55 ERBB2 55 underwent liver transplantation 55 PROSTVAC TM 55 Inhaled nitric oxide 55 Relapsed Refractory 55 apolipoprotein E4 55 endocrine responsive 55 ERK signaling 55 CTAP# Capsules 55 AGILECT R 55 CDKN2A 55 hyperphenylalaninemia HPA due 55 idiopathic PAH 55 PROLARIS 55 portal vein thrombosis 55 CCyR 55 bronchopulmonary dysplasia 55 precancerous condition 55 allogeneic hematopoietic stem cell 55 neurobehavioral disorder 55 neovascularisation 55 spinocerebellar ataxia type 55 hereditary pancreatitis 55 HLA DR4 55 recurrent glioma 55 lymphoproliferative diseases 55 monogenic disorders 55 Wisconsin Sleep Cohort 55 DNA hypermethylation 55 Renal Cell Carcinoma 55 KRAS mutation 55 ONCONASE R 55 antimetabolites 55 neurological manifestations 55 antiphospholipid antibodies 55 adverse cytogenetics 55 multiorgan 55 bortezomib Velcade 55 adjuvant cisplatin 55 congenital toxoplasmosis 55 spontaneous regression 55 Systemic lupus erythematosus SLE 55 perioperative complications 55 pT2 55 nodal metastasis 55 neurogenic bladder 55 HCV infection 55 oral Hycamtin 55 Tasigna prolongs 55 Golimumab 55 ferroportin levels 55 Waldenstrom Macroglobulinemia 55 Etanercept 55 evaluating tivozanib 55 Bezielle 55 endocrine dysfunction 55 nondemented 55 Follicular lymphoma 55 hyperprolactinemia 55 #p#.# [002] 55 endothelin receptor 55 Chronic Heart Failure 55 multivariable adjusted 55 idiopathic thrombocytopenic purpura ITP 55 paraganglioma 55 cutaneous melanoma 55 hepatic cirrhosis 55 BRCA1 BRCA2 55 hepatocellular carcinoma 55 Fatty liver 55 Cancer Epidemiol Biomarkers Prev 55 missense mutations 55 PIGF 55 Pegylated Interferon 55 Antitumor Activity 55 5-fluorouracil/leucovorin 55 transthyretin TTR mediated amyloidosis 55 breast cancer metastasis 55 SNT MC# 55 chronic myocardial ischemia 55 Hurler syndrome 55 Adult Stem Cell Therapy 55 internalizing disorders 55 Patient Registry 55 neuropsychiatric disorder 55 MAGE A3 ASCI 55 pathophysiological effects 55 prospectively defined 55 PSADT 55 artery stenosis 55 phthalate syndrome 55 ara C 55 neurocognitive dysfunction 55 prolonged QT interval 55 chromosomal rearrangement 55 peritoneal carcinomatosis 55 variceal bleeding 55 RET PTC rearrangements 55 postintervention 55 recurrent VTE 55 systemic anaplastic large 55 echocardiographic parameters 55 Exelixis XL# 55 cytogenic 55 pathological hallmarks 55 T1c 55 ACTEMRA TM 55 Cutaneous T 55 chromium supplementation 55 lupus nephritis 55 acute myelogenous 55 unfavorable cytogenetics 55 atypical parkinsonism 55 Severe Primary IGFD 55 adjuvant therapies 55 cabazitaxel 55 Immunotherapeutic 55 subclinical hypothyroidism 55 chemoresistant 55 paraneoplastic 55 DBMD 55 chemosensitivity 55 PDE# inhibitors 55 inducible nitric oxide synthase 55 Benign breast 55 ventricular dysplasia 55 Nephrotic Syndrome 55 inherited neurodegenerative 55 farletuzumab 55 cholestasis 55 TNF alpha selectively neutralizing 55 FDG PET imaging 55 YONDELIS 55 Alzheimer disease cognitive impairment 55 hypermethylated 55 rhabdoid 55 hematologic disorders 55 HHV 6 55 intensive lipid lowering 55 atypical ductal hyperplasia 55 N Myc 55 decompensated cirrhosis 55 CSF biomarkers 55 serum estradiol 55 GOUT 55 Fludara ® 55 fluoroquinolone resistance 55 antithrombotic agents 55 Idiopathic Pulmonary Fibrosis 55 ALK inhibitors 55 NNRTI resistance 55 inhaled corticosteroid therapy 55 median survivals 55 curative therapy 55 airway hyperresponsiveness 55 Jill Stautner 55 hyper IgE syndrome 55 prospective multicentre 55 FTLD 55 relapsing multiple sclerosis 55 faulty BRCA2 gene 55 Stage IIB 55 phenotypic expression 55 hypoperfusion 55 Treg cell 55 leukemia lymphoma multiple myeloma 55 Non Hodgkins lymphoma 55 recurrent GBM 55 Genetic mutation 55 serum phosphate 55 Antisoma AS# 55 transgenic mouse models 55 alexithymia 55 immunodeficiencies 55 motor neuron diseases 55 Non Hodgkin 55 cetuximab Erbitux 55 intracerebral haemorrhage 55 Becker muscular dystrophy 55 H pylori 55 rindopepimut 55 gene polymorphism 55 follicular Non Hodgkin 55 systemic juvenile idiopathic 55 AEG# 55 demonstrated antitumor activity 55 potentially modifiable 55 tumorigenicity 55 heritable diseases 55 tipranavir ritonavir 55 sensory gating 55 trial evaluating PRX# 55 urate levels 54 juvenile idiopathic arthritis 54 colorectal bowel 54 leukemia CLL 54 anal HPV 54 Erythropoietic therapies may 54 metabolic disturbances 54 mRNA decay 54 acute myocardial infarctions 54 Spokeswoman Amy Cianciaruso 54 hepatitis C genotype 54 metastatic castration resistant 54 breast carcinoma 54 epigenetic therapies 54 synaptic function 54 hematopoietic malignancies 54 leukemic stem cells 54 thrombophilia 54 gp# vaccine 54 KRAS mutant tumors 54 multivariate adjustment 54 INTEGRILIN 54 pancreatectomy 54 sporadic ALS 54 cisplatin chemotherapy 54 macrovascular events 54 pegylated liposomal doxorubicin 54 invasive aspergillosis 54 HGPS 54 FSGS 54 TNFalpha 54 macrovascular disease 54 Shortened telomeres 54 hematologic parameters 54 Bisphosphonate 54 BR.# 54 Cohort Consortium 54 adenoma recurrence 54 dysglycemia